Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 5/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31172692 | 1.00 | NFE2L2 (0.42) | NFE2L2CA2CA1ACHEPTGES2 | |
| SCHEMBL8740250 | 0.85 | NFE2L2 (0.43) | NFE2L2MAOBSLC22A12PTGS2AR | |
| SCHEMBL6630905 | 0.83 | NFE2L2 (0.42) | NFE2L2MAOBSLC22A12ARGAA | |
| SCHEMBL8854736 | 0.83 | NFE2L2 (0.42) | NFE2L2MAOBSLC22A12ARGAA | |
| SCHEMBL29469930 | 0.83 | SLC22A12 (0.37) | CA2PTGES2SLC22A12 | |
| SCHEMBL6807395 | 0.82 | CA2 (0.51) | CA2CA1ACHEPTGES2CA12 | |
| SCHEMBL16572564 | 0.82 | CA1 (0.47) | CA2CA1PTGES2CA12CA9 | |
| SCHEMBL8854731 | 0.81 | NFE2L2 (0.40) | NFE2L2MAOBSLC22A12ARGAA | |
| SCHEMBL31172602 | 0.80 | ADRA1D (0.48) | CA2CA1ACHEPTGES2CA12 | |
| SCHEMBL5399765 | 0.77 | PTGES2 (0.54) | NFE2L2CA2CA1ACHEPTGES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7723266-B2 | Substituted aryl sulphony(thio)ureas used as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2010-05-25 | — | — | US | disclosed |
| EP-1683789-A1 | Substituted arylsulfonyl(thio)ureas as herbicides | Bayer CropScience AG (DE) | 2006-07-26 | — | — | EP | disclosed |
| US-20050004123-A1 | Substituted aryl sulphonyl(thio)ureas used as herbicides | BAYER AG (DE) | 2005-01-06 | — | — | US | disclosed |
| US-6838414-B2 | Substituted aryl sulphonyl(thio)ureas used as herbicides | BAYER AKTIENGESELLSCHAFT (DE) | 2005-01-04 | — | — | US | disclosed |
| US-20030153463-A1 | Substituted aryl sulphonyl(thio)ureas | GESING ERNST RUDOLF F (DE) | 2003-08-14 | — | — | US | disclosed |
| US-6451737-B1 | N-(4,6-DIMETHYL-PYRIMIDIN-2-YL)-N'-(2-METHOXY-6-TRIFLUOROMETHY L-PHENYLSULPHONYL)-UREA | BAYER AKTIENGESELLSCHAFT (DE) | 2002-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153463-A1 | Substituted aryl sulphonyl(thio)ureas | TST, DDT, CBR3 | NFE2L2 920/4885CA2 1503/4885CA1 3162/4885 |
| US-20050004123-A1 | Substituted aryl sulphonyl(thio)ureas used as herbicides | DDT, CBR3, TST | NFE2L2 886/4885CA2 1414/4885CA1 2880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.